Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients.

Last updated: 16.7.2025
Grant

This Horizon Europe research and innovation action focuses on advancing the understanding and treatment of poorly-understood cancers across all age groups. It aims to leverage innovative research and digital technologies to improve immune system-centred interventions and overall cancer care. The program fosters a collaborative approach, encouraging synergies with existing EU initiatives to achieve a significant societal impact.

Who is Funded: Cancer Research & Care Beneficiaries

The program primarily targets research and health professionals, innovators, and related organizations across all EU Member States and Associated Countries, aiming to improve cancer understanding, prevention, diagnostics, treatment, and patient quality of life.

What is Funded: Research & Innovation in Oncology

This program funds research and innovation projects focused on poorly-understood cancers, emphasizing immune system-centred therapies and leveraging advanced digital technologies. The scope covers fundamental research through to implementation in health systems, allowing for comprehensive advancements in cancer care.

Type and Scope of Funding for Cancer Initiatives

The funding is provided as grants, with significant amounts allocated per project to support in-depth research and innovation. The program is designed to facilitate substantial contributions towards its cancer mission objectives.

Conditions & Requirements for Cancer Mission Proposals

Applicants must adhere to general Horizon Europe conditions, including specific thresholds for evaluation. Collaboration in consortia is required, with an emphasis on integrating socio-economic and humanities expertise.

Application Procedure: Streamlined Submission & Evaluation

The application process involved a single-stage submission. Proposals were rigorously evaluated against specific criteria, with an emphasis on scientific excellence and societal impact. Evaluation results were communicated to applicants in August 2023.

The program operates under the comprehensive legal framework of Horizon Europe, ensuring compliance with EU regulations and strategic objectives for research and innovation.

Similar Programs

#Cancer Research#Immune Therapies#Tumour-Host Interactions#Horizon Europe#Health Innovation#Cancer Treatment#Childhood Cancer#Adolescent Cancer#Adult Cancer#Elderly Cancer#Cancer Diagnostics#Quality of Life#Digital Health#Artificial Intelligence#Machine Learning#Data Platforms#Cancer Prevention#Healthcare Systems

Funding Overview

Funding Status

Funding Status:

Closed

Maximum Amount

Maximum Amount:

12,000,000 €

Allocated Budget

Allocated Budget:

Total for topic: 36,682,904.01 €. Individual projects: 7,000,000 € to 12,000,000 €.

Open Until

Open Until:

31.12.2027

Award Channel

Award Channel:

Framework Programme Call

Region

Region:

EU Member States and Associated Countries.

Sectors

Sectors:

Healthcare, Medical Technology, Research and Development, Information and Communication Technology, Other

Beneficiaries

Beneficiaries:

Cancer patients (childhood, adolescent, adult, and elderly), cancer survivors and their families, and society in general.

Application Type

Application Type:

Consortium Required

Funding Stages

Funding Stages:

Basic Research, Applied Research, Experimental Development, Prototyping, Product Development, Implementation, Service Delivery, Policy Development, Capacity Building, Awareness Campaigns

Funding Provider

Program Level:

European Union

Funding Body:

European Commission

Additional Partners:

HealthyCloud, EOSC-Life, Photonics21 partnership (including Photon Hub Europe support service), Innovative Health Initiative partnership, European Health Data Space (EHDS) Joint Action, 1+ Million Genomes (1+MG), Beyond One Million Genomes (B1MG), EBrains research infrastructure, EIT Health Knowledge Innovation Community initiatives, EOSC4cancer, canSERV, other EU programmes, and the Knowledge Centre on Cancer (KCC).

0 x 0
XS